Ultragenyx Pharmaceutical’s (RARE) Neutral Rating Reaffirmed at Wedbush

Wedbush reaffirmed their neutral rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $25.00 target price on the biopharmaceutical company’s stock.

RARE has been the subject of several other research reports. Bank of America dropped their price objective on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 21st. Truist Financial cut their price objective on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Jefferies Financial Group lowered their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research note on Tuesday, December 30th. Finally, Barclays dropped their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, November 24th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $71.18.

Ultragenyx Pharmaceutical Trading Down 1.7%

Shares of NASDAQ:RARE opened at $20.18 on Tuesday. The company has a 50 day moving average of $26.27 and a 200 day moving average of $29.66. The stock has a market cap of $1.95 billion, a P/E ratio of -3.46 and a beta of 0.16. Ultragenyx Pharmaceutical has a 12 month low of $18.41 and a 12 month high of $45.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.00 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.The business’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.39) earnings per share. On average, equities analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 3,081 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total value of $112,086.78. Following the completion of the sale, the chief financial officer directly owned 95,146 shares in the company, valued at approximately $3,461,411.48. The trade was a 3.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 6,227 shares of company stock worth $187,126 over the last quarter. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the business. Assetmark Inc. lifted its stake in Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares during the last quarter. Huntington National Bank increased its holdings in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares during the period. Danske Bank A S bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. Smartleaf Asset Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,169 shares during the period. Finally, Covestor Ltd grew its position in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 369 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on RARE while lowering its price target from $60 to $50, signaling continued analyst conviction in the company’s upside despite the cut. HC Wainwright lowers PT but maintains Buy
• Positive Sentiment: Coverage pieces highlight Ultragenyx’s strong rare-disease pipeline and sizable upside potential, reinforcing longer-term bullish views that may attract investors focused on pipeline value. Pipeline-driven bullish coverage
• Neutral Sentiment: Wedbush reaffirmed a Neutral rating with a $25 price target, suggesting some analysts see limited near-term catalysts while others remain constructive — this creates mixed signals for traders. Wedbush reaffirms Neutral
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors to join a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering purchases from Aug 3, 2023 to Dec 26, 2025; the lead-plaintiff deadline is April 6, 2026 — this legal overhang can pressure the stock and increase perceived risk. KSF class action notice Rosen Law Firm notice Schall Law Firm notice Robbins Geller notice Kessler Topaz complaint Faruqi & Faruqi reminder
• Negative Sentiment: Ultragenyx announced a roughly 10% workforce reduction as it targets profitability in 2027; while cost cuts could improve longer-term margins, layoffs and execution risk typically weigh on near-term sentiment. Workforce reduction announcement

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.